Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Liteng Shen"'
Autor:
Yu Guo, Zheyuan Shen, Wenbin Zhao, Jialiang Lu, Yi Song, Liteng Shen, Yang Lu, Mingfei Wu, Qiuqiu Shi, Weihao Zhuang, Yueping Qiu, Jianpeng Sheng, Zhan Zhou, Luo Fang, Jinxin Che, Xiaowu Dong
Publikováno v:
Advanced Science, Vol 11, Iss 13, Pp n/a-n/a (2024)
Abstract Bystander‐killing payloads can significantly overcome the tumor heterogeneity issue and enhance the clinical potential of antibody‐drug conjugates (ADC), but the rational design and identification of effective bystander warheads constrai
Externí odkaz:
https://doaj.org/article/0b332f6662be4abf81d980d05b305c7d
Autor:
Tingting Jin, Wei Xu, Roufen Chen, Liteng Shen, Jian Gao, Lei Xu, Xinglong Chi, Nengming Lin, Lixin Zhou, Zheyuan Shen, Bo Zhang
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
G2/M cell cycle checkpoint protein WEE1 kinase is a promising target for inhibiting tumor growth. Although various WEE1 inhibitors have entered clinical investigations, their therapeutic efficacy and safety profile remain unsatisfactory. In this stud
Externí odkaz:
https://doaj.org/article/b4791d4745624695875990f0deb7b536
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
The JAKs protein family is composed of four isoforms, and JAK3 has been regarded as a druggable target for the development of drugs to treat various diseases, including hematologic tumors, cancer, and neuronal death. Therefore, the discovery of JAK3
Externí odkaz:
https://doaj.org/article/9430dbcc5edb4d9e8cae17e1aa9ffaf3
Autor:
Chenpeng Yao, Zheyuan Shen, Liteng Shen, Kailibinuer Kadier, Jingyi Zhao, Yu Guo, Lei Xu, Ji Cao, Xiaowu Dong, Bo Yang
Publikováno v:
Pharmaceuticals, Vol 16, Iss 10, p 1459 (2023)
JNK3, a member of the MAPK family, plays a pivotal role in mediating cellular responses to stress signals, with its activation implicated in a myriad of inflammatory conditions. While JNK3 holds promise as a therapeutic target for neurodegenerative d
Externí odkaz:
https://doaj.org/article/5b7ee7ebabc24a489e323a750eea37a7